. Viral PAMPs are detected by the cytoplasmic RLH receptors RIG-I (also known as DDX58) and MDA-5 (also known as IFIH1), which signal through the mitochondrial protein MAVS, resulting in the activation of interferon regulatory factor 3 (IRF3) and NF-kB and type-1 interferon transcription [1] [2] [3] [4] [5] [6] . Abrogation of MAVS expression or function leads to reduced type 1 interferon production and antiviral protection 15 .
To study the potential role of NLR proteins in regulating mitochondrial antiviral signalling, we used bioinformatics to identify NLRs localized to the mitochondria. We identified one putative mitochondrial NLR called NLRX1 (previously known as CLR11.3 and NOD9) 9, 16 (Fig. 1a) . The predicted peptide sequence and distinct domains of NLRX1 are shown in Supplementary Fig. 1 . Consistent with the conserved motif structure of the NLR family, NLRX1 contains a central putative NBD and carboxy-terminal LRRs. The assignment of the amino-terminal effector domain to a subclass is less clear. Instead, the N terminus has evolved to include a mitochondrialtargeting sequence ( Supplementary Fig. 1 ). On the basis of hydrophobicity analyses, we identified two putative transmembrane regions ( Supplementary Fig. 2 ). NLRX1 homologues were identified in all vertebrates examined, with a remarkably high (92.4%) degree of conservation between human and mouse ( Supplementary Fig. 3 ).
To investigate NLRX1 function, NLRX1 was isolated and the complementary DNAs encoding N and C termini were verified by rapid amplification of cDNA ends (RACE). The 39 RACE produced two products, identifying a splice variant lacking a portion of the LRR region encoded by exon 9 ( Supplementary Fig. 4 ). NLRX1 messenger RNA is broadly expressed, suggesting a ubiquitous role (Supplementary Fig. 5 ). To examine protein expression, we generated an anti-NLRX1 monoclonal antibody. Antibody specificity was verified by immunoblotting against transfected, epitope-tagged haemagglutinin (HA)-NLRX1 or another NLR protein HA-NLRP12 (also known as Monarch1; ref. 17) . NLRX1 antibody detected a strong band corresponding to the exogenous HA-tagged NLRX1 ( Supplementary Fig. 6 ) and a weaker endogenous product of similar size in cells transfected with pcDNA or with HA-tagged NLRP12 (Supplementary Fig. 6 ). Short interfering RNA (siRNA)-mediated knockdown of NLRX1 greatly reduced the detection of this endogenous product, whereas control siRNA oligonucleotides had no effect ( Supplementary Fig. 7 ). NLRX1 protein was also detected in all cell lines analysed, further suggesting ubiquitous expression ( Supplementary Fig. 8 ).
Additional clues to NLRX1 function are revealed by its cellular localization. Both endogenous and overexpressed NLRX1 revealed a punctate cytoplasmic distribution ( Fig. 1b and Supplementary Fig.  9a ). Biochemical fractionation verified that endogenous NLRX1 protein resided in the non-nuclear fraction (Fig. 1c, middle panel) . This fraction contains both cytosol and cytoplasmic organelles, the latter of which include the mitochondria. Separation of this cytoplasmic/ organellar fraction into three fractions (small membranes, soluble cytosol and mitochondria) revealed that NLRX1 was found exclusively in the mitochondrial fraction, which also contained the mitochondrial protein TOM20 (translocase of outer mitochondrial membrane 20 homologue; also known as TOMM20) (Fig. 1c, right  panel) . A merged confocal image of endogenous NLRX1 and the mitochondrial stain Mitotracker indicated mitochondrial localization of NLRX1 ( Supplementary Fig. 9b ). Antibody staining by immunogold-bead electron microscopy was used as the ultimate method for visualizing NLRX1; this localized NLRX1 to the mitochondria with little staining elsewhere (Fig. 1d, top panels) . Costaining for NLRX1 (small beads) and MAVS (large beads) identified several mitochondria containing both proteins (Fig. 1d , middle panels). Isotype control antibody showed no nonspecific staining (Fig. 1d, bottom left panel) , whereas the positive control TOM20 showed mitochondrial staining (Fig. 1d , bottom right panel). As observed for MAVS and TOM20, many of the NLRX1-specific immunogold beads were proximal to the mitochondrial membrane. To study this further, we separated mitochondrial membrane fractions by a sucrose gradient (Fig. 1e) . Voltage-dependent anion channel 1 (VDAC1) and MAVS are proteins known to reside in the mitochondrial outer membrane and served as positive controls 1, 18 . VDAC1, MAVS and NLRX1 were the only proteins detected in fractions 1-5, which includes primarily mitochondrial outer membrane proteins (Fig. 1e) . COXIV (cytochrome c oxidase subunit IV isoform 1; also known as COX4I1) is an inner membrane mitochondrial protein and was only found in fractions 6-10. To confirm this finding, a trypsin protection assay was performed on prepared mitochondrial fractions.
NLRX1 and the known outer membrane proteins MAVS and BCL2L1 were all sensitive to proteolytic cleavage by trypsin, whereas the mitochondrial inner membrane protein COXIV was completely protected (Fig. 1f) . Furthermore, deletion of the N-terminal mitochondrial targeting sequence resulted in a loss of mitochondrial localization ( Supplementary Fig. 10 ). These results indicate that NLRX1 resides in the outer mitochondrial membrane.We next examined the interaction of NLRX1 and MAVS. Co-immunoprecipitation studies demonstrate that HA-NLRX1 interacts with MAVS ( Fig. 2a) but not with other known mitochondrial outer membrane proteins (BCL2 and BCL2L1), indicating specificity of the NLRX1-MAVS interaction (Fig. 2b) . Finally, endogenous NLRX1 associates strongly with endogenous MAVS after immunoprecipitation with two different MAVS antibodies (Fig. 2c) . Consistent with these results, MAVS and NLRX1 show a remarkably similar expression level in many cell types ( Supplementary Fig. 11 ).
NLRX1 and MAVS are both modular proteins; therefore, we sought to investigate the specific domains required for this interaction. The
Cell homogenate . It is also required for the interaction with NLRX1 (Fig. 2d) . In NLRX1, deletion of the LRR had no effect on the NLRX1-MAVS interaction. A further deletion of the putative NBD disrupted this interaction, indicating that this domain is required for maintaining the interaction with MAVS (Fig. 2e) .
Collectively, these data demonstrate that NLRX1 is a MAVS-associated mitochondrial outer membrane protein and raise the intriguing possibility that it participates in antiviral signalling.
Signalling in response to the synthetic viral double-stranded RNA (dsRNA) analogue poly(I:C) is mediated both at the cell membrane through Toll-like receptor 3 (TLR3) and within the cytoplasm by means of direct binding to the RLH molecules to activate MAVS. Both pathways activate NF-kB and IRF3, leading to interferon b (IFN-b) transcription 5 . Poly(I:C), cannot activate IFN-b expression in TLR3-deficient 293T cells when applied extracellularly. However, when delivered into the cytoplasm by transfection, poly(I:C) stimulates IFN-b through the MAVS pathway. Conversely, stable TLR3-expressing 293T cells have a robust response to extracellular poly(I:C), which does not require MAVS signalling. We used these two cell lines in poly(I:C)-induced IFN-b luciferase experiments to delineate a role for NLRX1 in intracellular (RLH) versus extracellular (TLR) antiviral responses. NLRX1 had no effect on the TLR3-mediated extracellular activation of IFN-b or NF-kB luciferase repor- LETTERS ters (Fig. 3a, top and bottom left panels) . By contrast, the intracellular IFN-b response was strongly inhibited by NLRX1 (Fig. 3a, top right  panel) . NF-kB luciferase reporter activation was likewise reduced, although to a lesser extent (Fig. 3a, bottom right panel) . Thus, NLRX1 acts as a negative regulator within the intracellular antiviral pathway. We next sought to study MAVS activation of IFN-b directly. MAVS potently activated the IFN-b reporter luciferase, and NLRX1 inhibited this activation in a dose-dependent fashion (Fig. 3b, left) . MAVS-induced NF-kB luciferase activity was inhibited by NLRX1, but to a lesser extent (Fig. 3b, right) . As a specificity control, p53 luciferase reporter was not affected by NLRX1 (Fig. 3c) . Other NLR proteins (CIITA, NOD2 and NLRC3 (also known as CLR16.2)) did not significantly affect IFN-b luciferase (Fig. 3d) . Expression of the constitutively active truncation mutant DRIG-I induces a robust intracellular antiviral response through MAVS 19, 20 . NLRX1 significantly reduced the ability of DRIG-I to activate IFN-b transcription (Fig. 3e, left) . MDA-5 is the intracellular receptor for poly(I:C) and picornavirus nucleic acid and also requires MAVS 6 . NLRX1 also abolished MDA-5 activity (Fig. 3e, right) . Furthermore, mapping of the NLRX1 functional domain revealed that the C-terminal LRR domain is required for the repression of MAVS-induced interferon signalling (Fig. 3f) . These data indicate that NLRX1 functions as an inhibitor of RLH-mediated MAVS antiviral signalling through the NLRX1 LRR domain.
To confirm that endogenous NLRX1 also repressed IFN-b production, NLRX1-specific siRNA oligonucleotides, which reduced NLRX1 protein by greater than 90% (Supplementary Fig. 7 ), were used. As expected, IFNB and IFNA mRNA levels rose sharply by 16 h post-transfection with MAVS. Both interferons were significantly increased in cells containing NLRX1 siRNA (Fig. 4a) . This increased MAVS-mediated response was also observed with the NF-kBresponsive genes interleukin 6 (IL6), RANTES (also known as CCL5) and tumour necrosis factor a (TNFa), although to a lesser extent, consistent with the aforementioned NF-kB luciferase data (Fig. 4a) . To test the effect of NLRX1 during a viral infection, IFNB mRNA and protein levels were quantified in NLRX1-deficient cells infected with Sendai virus, which activates RIG-I and MAVS for type-1 interferon production 1 . IFNB mRNA induction by Sendai virus was increased .8-fold in cells with NLRX1 siRNA compared with control siRNA (Fig. 4b, left) . Consistent with the transcriptional data, the Sendai-virus-induced IFN-b protein level was also greater in the infected NLRX1 siRNA cells (Fig. 4b, right) . In addition, NLRX1 expression attenuated MAVS, DRIG-I and Sendai-virus-induced IRF3 dimer formation, indicating that NLRX1 reduced MAVSmediated IRF3 signalling (Fig. 4c) .
To identify a mechanism for the inhibitory effect of NLRX1 on antiviral signalling, we examined the effect of NLRX1 on the endogenous association of MAVS with RIG-I. The interaction of MAVS and RIG-I was enhanced by Sendai viral infection, whereas the introduction of NLRX1 eliminated this enhancement (Fig. 4d) . Because this RLH-MAVS interaction is required for signalling, the disruption of this interaction by NLRX1 should squelch further downstream antiviral signalling. We extended these results by measuring cell death, viral replication and IFN-b production in NLRX1 siRNA cells infected with the human alphavirus Sindbis. In congruence with the Sendai-virus findings, NLRX1 siRNA cells infected with Sindbis produced more IFN-b protein than control siRNA cells (Fig. 4e, left) and the cells were highly resistant to green fluorescent protein (GFP)-Sindbis viral replication (25.06%) compared with the control siRNA cells (83.87%) (Fig. 4e, right) . The differences in cell death are not significant and therefore can not account for the large difference in viral susceptibility (Supplementary Fig. 12 ). Cumulatively, these observations solidify the negative regulatory role of NLRX1 in MAVS-mediated antiviral responses, and demonstrate that it is mediated through the inhibition of virus-induced RLH-MAVS interactions. Interestingly, NLRX1 mRNA and protein levels are stable after activation of MAVS signalling ( Supplementary Fig. 13) ; therefore, the regulation of NLRX1 apparently does not involve simple transcriptional or translational mechanisms. This report shows a linkage between the rapidly emerging NLR family and mitochondrial antiviral signalling. We speculate that the mitochondrial membrane provides a convenient surface on which antiviral cell-signalling complexes are arranged and activated. Rather than directly engaging a pathogen-derived product, NLRX1 seems to function as a modulator of PAMP receptors (MOPR) by affecting the interaction of the pathogen receptor RIG-I (and possibly MDA-5) with MAVS. This mechanism is more in-line with the Guard hypothesis proposed for the indirect detection of pathogen products by plant R proteins 21, 22 . Because both NLRX1 and RIG-I interact with the CARD domain of MAVS, a probable scenario is that NLRX1 and RIG-I compete for binding with the CARD domain of MAVS, with opposing outcomes. Because MAVS is a potent activator of type 1 interferon, a brake within this mitochondrial signalling complex could prevent unwarranted deleterious antiviral responses and regulate interferon signalling during the course of a viral infection. This report shows that NLRX1 is such a brake. It further demonstrates that targeting of NLRX1 through approaches such as siRNA could enhance antiviral responses, which has broad implications for the treatment of viralassociated diseases.
METHODS SUMMARY

Cloning of NLRX1.
A complete open reading frame of human NLRX1 was isolated from Jurkat cDNA using standard PCR techniques. The complete N and C terminals were verified by RACE. Expression data and antibody production. Expression data for NLRX1 were mined from the Genomics Institute of the Novartis Research Foundation. Recombinant hexahistidine-tagged NLRX1 was used as an antigen for the production of monoclonal antibody. NLRX1 antigen was injected into mice and monoclonal antibodies were produced by standard methodology. Real-time PCR. First-strand cDNA was generated from total RNA using random priming and moloney murine leukemia virus (MMLV) reverse transcriptase (Invitrogen). Real-time PCR was performed using QuantiTect SYBR Green PCR Master Mix (Qiagen) in triplicate experiments and analysed on an AB Prism 7700 analyser (Applied Biosystems). All real-time values were normalized to 18S ribosomal RNA. Immunofluorescent staining, immunogold and mitochondrial localizations. HeLa cells were transfected with 1.0 mg per well GFP-NLRX1 or stained with NLRX1 antibody. Anti-mouse Alexa Fluor 488 (Molecular Probes) was used to stain for endogenous NLRX1. All exogenous and endogenous NLRX1 localizations were visualized on a Zeiss LSM5 PASCAL confocal microscope. To determine co-localization with mitochondria, HeLa cells were co-stained with Mitotracker (Invitrogen) and endogenous NLRX1. Transmission electron microscopy of anti-NLRX1 immunogold labelling was also performed by standard methods. NLRX1 protein was detected in sucrose gradient fractions and trypsin-treated mitochondrial fractions. Luciferase assays, co-immunoprecipitations and siRNA. HEK293T or TLR3-HEK293T cells were transfected in 96-well plates with IFN-b, NF-kB or p53 luciferase constructs and HA-NLRX1. Exogenous MAVS, poly(I:C) or p53 plasmid was used as an agonist. All co-immunoprecipitation studies of exogenous and endogenous proteins were performed from whole cells lysed in RIPA buffer and following standard methodology. Non-targeting, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or NLRX1 siRNA oligonucleotides (Dharmacon) were transfected following the commercial protocol.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
